Important Note

CA 15-3 and CA 27-29 measure different epitopes of the same MUC1 glycoprotein. Clinical evidence supports using either test to monitor oncologic therapies, but not both.

On November 6th, 2018, new testing platform for testing CA 15-3 was implemented. CA 27-29 is no longer be performed on-site. It is highly recommended that patients are re-baselined whenever a change in test marker or testing platform is made. Therefore, all patients which have utilized CA 27-29 testing must be re-baselined to switch to CA 15-3 for ongoing monitoring.